Jubilant Ingrevia Q2 FY27 Earnings Call: EBITDA Jumps 51% on Record Revenue, Buys 40% Stake in ZetaOne (JUBLINGREA)

Jubilant Ingrevia Ltd held its Q2 FY27 earnings call on October 27, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Quarter with Broad-Based EBITDA Expansion

• Revenue of Rs.1,394 crore (+24% YoY) — an all-time quarterly high; EBITDA rose 51% YoY to Rs.221 crore (highest in three years) and PAT grew 60% YoY to Rs.111 crore in Q2 FY 2026-2027.
• H1 FY 2026-2027 momentum — revenue grew 25% YoY and EBITDA 44% YoY; quarterly EBITDA has more than doubled over the past 3 years, which management attributed to the Pinnacle strategy and disciplined cost management.
• Specialty chemicals revenue of Rs.560 crore (+16% YoY, +5% QoQ) — EBITDA of Rs.140 crore at a 25% margin, driven by improved pricing across value-added fine chemicals and CDMO.
• Nutrition & health solutions revenue of Rs.270 crore (+50% YoY, +11% QoQ) — EBITDA of Rs.39 crore (+87% YoY) at a 15% margin; vitamin D3 volumes strong and CCCBT pricing improved across EU, US, and India.
• Chemical intermediates revenue of Rs.563 crore (+24% YoY, +8% QoQ) — EBITDA of Rs.64 crore (+226% YoY) on improved realizations; acetic anhydride pricing up strong double digits YoY and ethyl acetate realizations improved significantly YoY and QoQ.
• Input cost offset — improved acetyls realizations were partially offset by higher input and utility costs amid elevated crude-driven input inflation.

40% Stake Opens Electronics & Semiconductor Ecosystem

• Rs.189 crore for a 40% stake in ZetaOne Technologies — agreement signed, with the shareholders agreement to be concluded soon; entry into the electronics design and manufacturing services space for a more integrated value proposition.
• ZetaOne expected to grow at least 60-70% in FY 2026-2027 — management hopes for possibly more; the business has doubled over the last few years, and a new manufacturing facility is being established near Bangalore.
• Semiconductor funnel up ~30% — joint go-to-market efforts have lifted Jubilant's semiconductor funnel by almost 30% in recent months (as of Q2 FY 2026-2027).
• Two-way synergies per management — ZetaOne brings customers and credentials combined with Jubilant's backward-integrated chemicals capability, while Jubilant provides manufacturing muscle to help scale ZetaOne's ramp-up far quicker.
• Vertical positioning undecided — management said it is too early to say whether ZetaOne is a new vertical or an expansion of existing capabilities and will "come back on that at the right time"; near-term priority is synergistic growth of the chemicals business.

Rs.2,000 Crore Peak Potential, Innovator Resolution Near

• 25+ confirmed molecules — converted from a 100+ molecule pipeline over the last four quarters (through Q2 FY 2026-2027); the pipeline is dynamic, with a few confirmations and some drop-offs each quarter.
• Rs.1,500 crore+ peak potential (ex-large contract) — commercial orders secured over the previous three quarters; at least one-third is targeted to be booked in FY 2026-2027, with Rs.500 crore expected to flow through in FY 2026-2027 and scaling hoped over FY 2027-2028 and FY 2028-2029.
• ~Rs.2,000 crore total peak potential — including incremental wins and the large agrochemical contract (period unspecified).
• Large contract first lot delivered — delivered as per the commitment and understanding with the customer; several scenarios for future volumes are under discussion and management is "very close" to concluding the way forward, with an investor update hoped within the next few weeks (Q3 FY 2026-2027). No take-or-pay commitment disclosed.
• Innovator risk addressed qualitatively — on the innovator's conversion of its revolving credit facility to secured (FY 2026-2027), CEO Deepak Jain declined to comment on the innovator's actions but said the company has a "very solid" agreement under which its risk is "fully protected"; no parent guarantee or LC details were disclosed.
• Volume visibility horizon unclear — management could not yet specify whether innovator visibility covers only the next few months or the entire 5-year contract duration.
• CDMO revenues almost doubled over the last two years (through Q2 FY 2026-2027, ex-large contract); the CDMO portfolio is at about one-third of its full potential in FY 2026-2027, with ramp hoped from FY 2027-2028.

Competitor Closure a Multi-Year Lever; Capex Run-Rate Maintained

• ~20% share in Europe acetic anhydride — Jubilant currently holds a high-teens share (as of Q2 FY 2026-2026); management's aspiration is to double this share over FY 2027-2028–FY 2028-2029 on the back of the Europe plant closure, "provided the plants remain shut" — the concerned company is yet to provide visibility on the shutdown, and the quantum is still being assessed.
• Uplift only from early CY 2027 — on the European plant corrosion development (closure emerged mid-September 2026), management views it as a multi-year opportunity and hopes for a "big blip" in FY28; how much is captured in FY 2026-2027 remains to be seen.
• H1 FY 2026-2027 capex of ~Rs.120 crore — management maintained guidance of investing at least Rs.400-500 crore every year (as announced a couple of years back in the investor presentation), averaging two new — ideally multipurpose — plants annually.
• Gajwala multipurpose plant — ready in the next few months (FY 2026-2027); the new multi-purpose plant remains on track for commissioning by end of FY 2026-2027 and is expected to strengthen the CDMO and fine chemicals roadmap. Additional capex is being conceptualized, subject to board approval.

Agrochemicals Muted, Vitamin B3 Seasonal Softness

• Agrochemicals under pressure — stable volumes but muted pricing in Q2 FY 2026-2027 due to excess capacity in China.
• Vitamin B3 pricing softening — animal feed segment pricing has softened over the past few weeks; over the last 3-5 years, vitamin B3 pricing has generally declined in Q3, a seasonal pattern repeating in the current quarter, and declines may linger into Q3 FY 2026-2027 with the margin impact yet to be quantified.
• Base pyridine/picoline pricing soft — volumes stable despite soft pricing; cost optimization and capacity debottlenecking expected to strengthen performance going forward.
• Consumer segment jumped significantly in Q2 FY 2026-2027 — driven by heavy focus on personal care, with the vitamin B3 personal care grade ramping quickly; consumer products remain only 7% of the overall portfolio, and management hopes to reach double digits within the next few quarters.
• Personal care and pharma strength — personal care delivered strong volume growth with traction from new customers seeking outsourcing partnerships; pharmaceuticals grew on steady volumes and sustained intermediates demand; semiconductors & electronics saw strong new-molecule pipeline growth, particularly in Japan.

FY27 Guidance Reaffirmed Toward Upper End

• Rs.750-800 crore FY 2026-2027 guidance reaffirmed — on the back of strong H1 FY 2026-2027 performance, management hopes to come in closer to the upper end of the range.
• 20-25% specialty chemicals growth is a multi-year CAGR aspiration (period unspecified), not a half-yearly run-rate; the combined specialty chemicals + nutrition EBITDA more than doubled over the last three years (>25% growth), and management is "reasonably confident" of maintaining that as a multi-year rate. H1 FY 2026-2027 specialty chemicals EBITDA growth of ~10% reflects the lumpy, project-driven nature of the business.
• 70%+ average utilization by end of FY 2026-2027 — investments made over the last 3-3.5 years will start reaching these levels, after which new plants (capex) are needed for incremental growth; management clarified it "probably did not say the peak" utilization.
• Growth expected across all three business segments in FY 2027 — management remains confident of sustaining momentum on the Pinnacle journey; higher acetyls volumes anticipated in FY 2027, supported by plant closures in Europe.
• Pricing outlook broadly stable — most segments are holding up prices and management is "hoping there should not be any negative impact" except possibly vitamin B3 into Q3 FY 2026-2027; revenue growth is not straight-line, as pricing and old-product delivery schedules also drive outcomes.